CD34+ Humanized Mice
Human cord blood-derived hematopoietic CD34+ stem cells. Validated: greater than 25% human CD45+ cells in peripheral blood. Humanized NSG variants (hu-CD34+). Infectious disease, gene therapy, cancer,
Watch Video
Latest Content
Welcome to our Hub! We hope you find something interesting to read, watch and share.
-
-
CAR T studies with significantly delayed onset of GvHD
Assessing efficacy and toxicity in CAR-T studies in an accessible translational model. The Jackson Laboratory's in vivo PBMC-humanized mouse platform provides a wider window to look at cytokine releas
Watch Video
-
CAR T-induced Immunotoxicity: Tackling the Cytokine Release Syndrome Challenge
In this special joint webinar, we discuss CAR T-induced Immunotoxicity, highlighting cutting-edge platforms for assessing the safety and efficacy of CAR therapies and preventing the development of CRS
Watch Video
-
Evidence-Based Selection of the Starting Dose in First-in-Human Clinical Trials Using Humanized Mouse Models
Read Flipbook
-
Neurofilament Light Chain Tech Sheet
Read Flipbook
-
Exploring Rare Disease Through Translational Research
Learn how mouse models help researchers disentangle the complexity of rare disease and help drive preclinical drug development.
Learn More
-
JAX Tech Talk Episode 63: Let's talk FcRn: The Translational Platform for Antibody PK Assessment (Apr. 25, 2023)
Learn the benefits of using the FcRn mouse model platform in characterizing the PK of your therapeutic, from the long half-life to the types of antibody therapeutics that can be screened.
Watch Video
-
Type1 Diabetes Efficacy Studies Tech Sheet
Read Flipbook
-
Lupus Efficacy Studies Tech Sheet
Read Flipbook
-
Psoriasis Efficacy Studies Tech Sheet
Read Flipbook
-
MS-EAE Efficacy Studies Tech Sheet
Read Flipbook
-
Translatable Efficacy & Safety Testing of mAb, Bispecific, & CAR T Therapies
Brian Soper, Ph.D. presents preclinical data demonstrating: Monoclonal antibody-based human immune modulation, donor-specific differences in bispecific antibody-mediated tumor efficacy and cytokine re
Watch Video
-
32nd Annual Short Course on Experimental Models of Human Cancer
Join us in person or virtually for JAX's signature cancer training program, August 14 – 22, 2023.
Learn More
-
2023 AACR Mouse models of cancer available from The Jackson Laboratory
Read Flipbook
-
2023 AACR Assessing individual variability in efficacy and toxicity of autologous and allogeneic chimeric antigen receptor T-cell immunother
Read Flipbook
-
2023 AACR Comparisons of Rituximab and CD19xCD3 BiTE antitumor response across multiple humanized NSG strains engrafted with human hematopoi
Read Flipbook
-
2023 AACR A new tumor-bearing humanized mouse model to evaluate the efficacy of bispecific T cell engager and monoclonal checkpoint antibodi
Read Flipbook
-
2023 AACR Novel preclinical model for the evaluation of cytokine release syndrome in response to CD19xCD3 bispecific antibody in humanized m
Read Flipbook
-
2023 AACR The use of PBMC humanized mice to test the efficacy and safety of antibody and cell-based cancer immunotherapeutics
Read Flipbook
-
Onco-Hu Studies
Read Flipbook
-
Loading More...
